Working Paper: NBER ID: w16295
Authors: Yi Qian
Abstract: Research on the effects of patent protection on innovation and technology transfer in the cross-country pharmaceutical industry adds to our understanding of the underlying forces driving a country's innovation level. Qian (2007) constructs a comprehensive database useful for evaluating the patenting effects on pharmaceutical innovations for 26 countries that established national pharmaceutical patent laws during the period from 1978 to 2002. This paper is a companion piece that extends the research to evaluating the effects of patent reforms on inward foreign direct investment (FDI) establishments and imports in the pharmaceutical sectors. This book chapter also attempts to integrate all the findings on innovations, technology transfer, and international trade, and discuss potential policy implications. \n\nBy thoroughly controlling for the country covariates, through a combination of matched sampling techniques with fixed-effect panel regression models, the analyses arrive at robust results across the various model specifications. First, national pharmaceutical patent protection alone does not stimulate domestic innovation, as estimated by the US patent awards (both raw counts and citation-weighted) and domestic R&D. FDI establishments and pharmaceutical exports did not increase significantly either. Imports, however, did flourish. Second, national patent law implementation demonstrates conditional importance for innovation acceleration and technology transfer, conditional upon certain country variables. In particular, the interaction between implementation and the development level, educational attainment, and economic freedom index are shown to have positive relationships with the domestic R&D expenditure and domestic pharmaceutical patent awards in the US. The interaction between implementation and economic freedom, implementation and educational attainment are indicated to attract more FDI establishments. Third, terms of trade is likely to decline immediately upon the new implementation of IPR.
Keywords: No keywords provided
JEL Codes: O34
Edges that are evidenced by causal inference methods are in orange, and the rest are in light blue.
| Cause | Effect |
|---|---|
| national pharmaceutical patent protection (O34) | domestic innovation (O39) |
| patent law implementation + educational attainment (O34) | domestic R&D expenditures (O32) |
| patent law implementation + economic freedom (K11) | domestic R&D expenditures (O32) |
| patent law implementation + educational attainment (O34) | pharmaceutical patent awards (O34) |
| patent law implementation + economic freedom (K11) | pharmaceutical patent awards (O34) |
| patent laws + freer economy + higher educational attainment (O39) | FDI (F23) |
| patent law implementation (O34) | imports of pharmaceuticals (L65) |